Clover Health Investments (CLOV) CLO Soares Sells $90K of Stock
Key Points
- Chief Legal Officer Karen Soares sold 19,275 shares of Clover Health stock on October 20, 2026, at $4.66 per share under a pre-arranged plan.
- After the trade, Karen Soares holds 1,573,423 $CLOV shares, down 1.21% from before the trade.
- The company trades above its 50-day and 200-day moving averages as it approaches its next financial results release on November 4, 2026.
- Wall Street firms hold mixed views on the healthcare plan provider, with analysts maintaining price targets between $5.00 and $6.00.
Get Clover Health Investments, Corp. text alerts
We text you when insiders, Congress, analysts or big funds move on $CLOV.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Clover Health Investments, Corp. alert may contain errors. Disclosures
Clover Health Investments, Corp. Chief Legal Officer Karen Soares sold 19,275 shares of company stock on October 20, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a price of $4.66 each, resulting in a total value of $89,821.50. The disposal was carried out under a pre-arranged Rule 10b5-1 trading plan. Following the transaction, Soares holds 1,573,423 shares of the healthcare company, cutting her stake by about 1.21%.
CLOV
Clover Health Investments, Corp.
Inside Karen Soares's Clover Health Trade
The transaction took place on October 20, 2026, with the stock closing at $4.80 on the same day. Soares executed the sale at $4.66 per share. This follows an earlier round of insider sales by company executives on October 15, 2026, which included prior transactions by Soares herself.
Other Institutional Activity in Clover Health
Large institutional funds have adjusted their holdings in the healthcare provider over recent reporting periods. Nuveen, LLC grew its holdings by 5,356,158 shares, ending with 6,291,699 shares worth about $30,200,156. At the same time, PNC Financial Services Group, Inc. reduced its stake by 200,251 shares, leaving it with 3,563,874 shares valued at roughly $17,106,595.
Clover Health Investments, Corp. Stock Up 7.4%
Clover Health shares closed at $4.80 on October 20, 2026, and recently traded around $4.81. The stock trades above both its 50-day moving average of $4.46 and its 200-day moving average of $3.45.
Recent Earnings
The company generated $2,475,912,960 in trailing twelve-month revenue with an EPS of -$0.05. Clover Health is scheduled to report its next round of financial results on November 4, 2026.
Dividend
Clover Health Investments, Corp. currently pays no dividend.
Insider Buying and Selling at Clover Health Investments, Corp.
Insider transactions at Clover Health recently included multiple sales by executives on October 15, 2026. CEO Jamie L. Reynoso sold 18,273 shares, Counterpart Health CEO Conrad Wai sold 23,627 shares, Chief Legal Officer Karen Soares sold 14,673 shares, and CEO Andrew Toy sold 62,176 shares. All of these prior sales were executed under planned trading arrangements.
Analysts Set New Price Targets
Wall Street firms maintain varied outlooks on the stock. Canaccord Genuity maintains a buy rating with a $5.50 price target set on July 21, 2026, while UBS holds a neutral rating with a $5.00 price target set on August 6, 2026. Overall, the company carries a consensus target mean price of $5.38 across four analyst opinions.
About Clover Health
Clover Health Investments, Corp. operates in the healthcare sector, providing Medicare Advantage plans to eligible individuals in the United States. The company offers preferred provider organization and health maintenance organization plans alongside its proprietary software platform, Clover Assistant, which helps physicians manage chronic diseases. Founded in 2014, the firm is headquartered in Wilmington, Delaware.
Bottom Line
Investors will watch for the company's upcoming earnings report on November 4, 2026, to gauge ongoing operational progress. Further insider filings and institutional reports will provide additional clues about how major stakeholders view the stock's valuation relative to its moving averages.
Related Filing Alerts
Source: Karen Soares's Form 4 filing on $CLOV (Oct 20, 2026). Written by software, not financial advice. How we make alerts